Drug Landscape ›
HUMAN IMMUNOGLOBULIN G ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 25,228
Most-reported reactions
Off Label Use — 4,238 reports (16.8%) Fatigue — 2,779 reports (11.02%) Covid-19 — 2,724 reports (10.8%) Headache — 2,513 reports (9.96%) Drug Ineffective — 2,344 reports (9.29%) Sinusitis — 2,281 reports (9.04%) Pneumonia — 2,279 reports (9.03%) Product Dose Omission Issue — 2,146 reports (8.51%) Inappropriate Schedule Of Product Administration — 2,135 reports (8.46%) Malaise — 1,789 reports (7.09%)
Source database →
HUMAN IMMUNOGLOBULIN G in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is HUMAN IMMUNOGLOBULIN G approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for HUMAN IMMUNOGLOBULIN G in United States?
Marketing authorisation holder not available in our data.